U.S. Markets closed

Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23%

Zacks Equity Research

Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 9% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $3.43 to $4.06 in the past one-month time frame.

The company has seen 1 negative revision in the past 1 month, while its Zacks Consensus Estimate of a loss widened over the same period, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Progenics Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other players in the healthcare industry include Illumina Inc. (ILMN), Gilead Sciences Inc. (GILD) and ANI Pharmaceuticals, Inc. (ANIP) all carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

PROGENICS PHARMA INC (PGNX): Free Stock Analysis Report

GILEAD SCIENCES INC (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report

Zacks Investment Research